Irish Pharmacists Report GLP-1 RA Counseling Gaps, Safety Concerns, and Training Needs for Obesity Management
Background
The global rise in obesity necessitates effective management strategies, with Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) emerging as a key pharmacological intervention. While GLP-1 RAs offer significant weight loss and metabolic benefits, their safe and effective use relies heavily on comprehensive patient education and support. Community pharmacists, as accessible healthcare professionals, play a crucial role in dispensing these medications and providing patient counseling. However, the specific challenges and support needs of pharmacists in delivering this care, particularly in the context of growing demand and evolving prescribing practices, remain underexplored, creating a gap in optimizing patient outcomes.
Study Design
Researchers conducted a cross-sectional study in Ireland, distributing an online questionnaire to community pharmacists in July 2025. The survey included both closed-ended questions, analyzed quantitatively using descriptive statistics, and open-ended questions, which underwent conventional content analysis. The study aimed to capture the experiences and perspectives of pharmacists regarding GLP-1 RAs for obesity management, focusing on their counseling practices, perceived barriers, and concerns. A total of 200 completed questionnaires were collected for analysis, providing a snapshot of current pharmacy practice.
Results
Of the 200 pharmacists surveyed, 16.1% (n=31) reported dispensing GLP-1 RAs specifically for obesity, while a substantial 82.9% (n=160) dispensed them for both obesity and diabetes management. Pharmacists frequently provided counseling on practical aspects of GLP-1 RA use, including storage (83.94%, n=162), administration (74.09%, n=143), and side effects (66.32%, n=128). Sharps disposal was discussed by 51.3% (n=99) of respondents. However, counseling on topics like nutrition and contraception was less frequent, with 45.6% (n=88) never providing contraception advice to female patients. Time constraints were identified as the primary barrier to comprehensive counseling. Pharmacists also highlighted significant challenges, including the impact of medication shortages, increased pressure on pharmacy workflows, and concerns regarding safety and prescribing oversight, particularly for online prescriptions. They also expressed a strong need for additional education and training.
82.9% of surveyed pharmacists dispensed GLP-1 RAs for both obesity and diabetes, indicating a broad role in metabolic health management.
Key Findings
- 82.9% of pharmacists dispensed GLP-1 RAs for both obesity and diabetes management.
- Counseling on GLP-1 RA storage (83.94%) and administration (74.09%) was frequent.
- 45.6% of pharmacists never provided contraception advice to female GLP-1 RA patients.
- Time constraints, medication shortages, and workflow pressure were major barriers to counseling.
- Pharmacists expressed concerns about online prescribing safety and a need for more education/training.
Why It Matters
This study underscores the critical, yet under-supported, role of community pharmacists in GLP-1 RA therapy. For peptide users and clinicians, it highlights potential gaps in patient education, particularly concerning lifestyle integration (nutrition) and specific health considerations (contraception). The findings suggest that current protocols for GLP-1 RA dispensing and patient support may be insufficient, leading to suboptimal adherence or safety. To improve clinical translation, updated professional guidance, enhanced pharmacy-based practice models, and national policies are urgently needed to empower pharmacists. This could involve structured training programs, dedicated counseling time, and clear guidelines for managing online prescriptions, ultimately leading to safer and more effective obesity care delivery.
ireland
glp-1-ra
obesity
pharmacy
pharmacist-perspectives
patient-counseling